KunyongYang

Associate

(T) + 1.858.314.1148

Kunyong Yang focuses his practice on the development and management of global patent portfolios involving pharmaceutical, chemical, and biotechnology innovations. He guides clients from the early stages of patent portfolio development, through the product development process, to the development of late-stage life cycle management strategies and regulatory extension opportunities. A particular focus of his practice is advising clients regarding intellectual property matters for small molecule drugs.

Kunyong also advises clients on due diligence matters, including providing patentability, validity, and freedom-to-operate analysis, in association with clients' investment in or acquisition of third parties, as well as licensing and collaboration opportunities. Kunyong also has experience in Hatch-Waxman litigation and patent post-grant proceedings, including inter partes review (IPR).

Representative clients include Celgene Corporation, Infinity Pharmaceuticals, and Takeda Pharmaceuticals. Particular small molecule pharmaceuticals that Kunyong has been involved with include REVLIMID®, ALUNBRIG® (brigatinib), and Duvelisib.

Prior to joining Jones Day, Kunyong worked at the Genomics Institute of the Novartis Research Foundation as a medicinal chemist.

Experience

  • Aprea Therapeutics completes $97 million IPOJones Day served as IP counsel in connection with the $97 million initial public offering of Aprea Therapeutics, Inc. (NASDAQ: APRE).
  • Celgene to be acquired by Bristol-Myers Squibb for approx. $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Takeda expands patent portfolio relating to anticancer drugs and clinical stage anticancer drug candidatesJones Day represents Takeda Pharmaceuticals U.S.A., Inc. in worldwide patent prosecution and portfolio development for approved and clinical stage anticancer drugs and drug candidates, including ALUNBRIGTM (brigatinib), which is indicated for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
  • Celgene successfully defends REVLIMID® compound patent against Kyle Bass' IPR petitionJones Day represented Celgene Corporation in successfully defending an IPR petition filed by Coalition for Affordable Drugs VI LLC (CFAD) - a company formed by hedge fund manager Kyle Bass - against U.S. Patent No. 5,635,517, which is listed in the Orange Book for Celgene's REVLIMID® brand drug.
  • Celgene defends REMS patents against Kyle Bass' IPR petitionsJones Day is representing Celgene Corporation in defending four IPR petitions filed by Coalition for Affordable Drugs VI LLC - a company formed by hedge fund manager Kyle Bass - against U.S. Patent Nos. 6,045,501 and 6,315,720, which are listed in the Orange Book for Celgene's REVLIMID®, POMALYST®, and THALOMID® brand drugs, and which pertain to Celgene's Risk Evaluation and Mitigation Strategy (REMS)™ for those drugs.
  • Infinity establishes global patent portfolio for small molecule inhibitors of FAAHJones Day assists Infinity Pharmaceuticals, Inc. in the establishment of a global patent portfolio related to small molecule inhibitors of fatty acid amide hydrolase (FAAH).
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.